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Axillary lymph node status is probably the single most important
prognostic indicator in breast cancer. Clinical evaluation of the
axilla is neither sensitive nor specific enough (Sacre, 1986) and
radiological tests including mammography, ultrasound scanning
and lymphoscintigraphy have not been useful in the preoperative
assessment of the axilla (Bruneton et al, 1986; McLean and Eye,
1986; Lam et al, 1996). Immunolymphoscintigraphy using radio-
labelled anti-breast cancer monoclonal antibodies achieved a
sensitivity of 86% and specificity of 92% (Tjandra et al, 1986a,
1986b), but it is unclear as to how accurate magnetic resonance
imaging of the axilla is. More recently, it has been reported that
positron emission tomography can be useful in detecting nodal
metastases with 79% sensitivity and 96% specificity for T1
tumours, but for tumours over 2 cm in diameter, these figures
improve to 94% and 100% respectively (Avril et al, 1996).
Surgical removal for histological assessment remains the best
and most accurate way to assess nodal status. Although it reduces
the incidence of tumour recurrence in the axillary lymph nodes,
axillary dissection remains controversial. Some advocate axillary
dissection for all patients with invasive breast cancers (Fentiman
and Mansel, 1991; Cabanes et al, 1992), whereas others have ques-
tioned the need for this procedure in patients with early tumours
(Silverstein et al, 1994). The anatomical extent and level of axil-
lary dissection has also been discussed extensively, with some
showing preference for complete axillary clearance (Fentiman and
Mansel, 1991) and others opting for partial dissection and
sampling of four lymph nodes (Steele et al, 1985; Greenall, 1995).
The latter approach, however, runs the risk of failing to accurately
stage the patient, with error rates as high as 24% (Kissin et al,
1982; Kjaergaard et al, 1985).
The aim of this study was to identify the primary histopatho-
logical tumour characteristics which correlate with axillary lymph
node metastases and determine whether they can be used to predict
axillary lymph node status and as criteria in selecting patients for
axillary dissection.
PATIENTS AND METHODS
This is a retrospective analysis of 909 patients with breast cancer
who underwent axillary lymphadenectomy in our unit over an 8-
year period, from June 1989 to June 1997. Over 95% of patients
with invasive cancer underwent a level 3 axillary clearance,
whereas a level 1 axillary dissection was performed in nearly all
cases of ductal carcinomas in situ (DCIS).
Axillary lymph node status was correlated with a range of
histopathological parameters:
a. Tumour size was the maximum diameter of the invasive
cancer measured macroscopically and confirmed micro-
scopically by the histopathologist and categorized using
the T value of the TNM system: T1a = 0–5 mm;
T1b = 6–10 mm; T1c = 11–20 mm; T2 = 21–50 mm;
T3 = > 50 mm
b. Histological type
c. Histological grade using the modified Bloom and
Richardson system (Elston and Ellis, 1991)
d. Lymphovascular invasion seen in vessels within the
primary tumour on haematoxylin and eosin slides
e. Oestrogen and progesterone receptor status assessed either
immunohistochemically (in the second half of the study
period) or by a radioimmunoassay (in the first half) and
was used to divide patients into four groups:
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• ER +ve/PgR +ve
• ER +ve/PgR –ve
• ER –ve/PgR +ve
• ER –ve/PgR –ve.
RESULTS
Four hundred and six patients (44.7%) of the total of 909 who had
axillary lymphadenectomy had nodal metastases and of these 229
(56.4%) had up to three nodes involved. Table 1 shows a detailed
breakdown of the histopathological parameters of the tumours of
all the patients included in this study.
Eight hundred and seventy-two (96%) of our patients had inva-
sive breast carcinomas and 77 of these fell into the ‘special types’
category, which included mucinous, medullary and tubular carci-
nomas or a combination of two types of invasive carcinomas.
Histological type and grade and tumour size were recorded for
every case in this study. However, in the first 2 years of this period
lymphovascular invasion was not recorded and hormone receptors
were not measured routinely and, therefore, these parameters are
not known for 118 and 236 patients respectively (Table 1).
Nearly half of invasive ductal and lobular carcinomas had posi-
tive axillary lymph nodes and as expected none of the ductal carci-
nomas in situ were associated with nodal metastases (Figure 1).
Histological grade was related to lymph node status, with only
25% of grade l tumours being associated with nodal metastases as
compared to 52.3% of grade III tumours (Figure 2). Tumour size
was also another important factor with positivity ranging from 0%
in T1a to 88.9% in T3 cancers (Figure 3).
When the last two parameters were combined together (Table
2), for T1b tumours positive axillary lymph nodes were found in
around 14% of grade I and grade II, as compared to 25% of grade
III tumours. For grade I T1c tumours only 26.7% had metastatic
disease in the axilla.
Table 1 Histopathological parameters of tumours in this study
Parameter n %
Histological type
Invasive ductal 709 78.0
Invasive lobular 86 9.5
Ductal in-situ 37 4.0
Special types 77 8.5
Histological grade
I 97 11.1
II 492 56.4
III 283 32.5
Tumour size (mm)
0–5 26 3.0
6–10 98 11.2
11–20 359 41.2
21–50 326 37.4
>50 63 7.2
Lymphovascular invasion
+ve 293 33.6
–ve 461 52.9
NK 118 13.5
Oestrogen/Progesterone receptors
+/+ 352 40.4
+/– 108 12.4
–/+ 37 4.2
–/– 139 15.9
NK 236 27.1
NK = not known.
Table 2 Breakdown of lymph node-positive cases according to tumour size
and histological grade
Tumour size (mm) Grade I – n (%) Grade II – n (%) Grade III – n (%)
0–5 0 (0) 0 (0) 0 (0)
6–10 3 (13.6) 9 (14.1) 3 (25)
11–20 12 (26.7) 79 (37.8) 37 (35.2)
21–50 8 (42.1) 114 (65.9) 84 (62.7)
> 50 2 (100) 28 (90.3) 26 (86.7)
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Figure 1 Axillary lymph node positivity (%) per histological type.
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Figure 2 Axillary lymph node positivity (%) per histological grade1976 C Yiangou et al
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A strong correlation was found between the presence of
lymphovascular invasion and axillary nodal metastases with 85%
of tumours exhibiting this feature being associated with a positive
axilla (Figure 4). Approximately 45% of patients with ER
+ve/PgR +ve tumours had positive axillary nodes, but absence of
one or both types of hormone receptors increased positivity by
about 8–13% (Figure 5).
Multifactorial analyses showed that only 6.4% and 10.7% of
patients with T1b and T1c tumours without lymphovascular
invasion, respectively, had axillary nodal metastases, whereas for
grade I T2 tumours without lymphovascular invasion the corre-
sponding figure was 30.7%. These figures are lower than the
corresponding figures in Figure 3 and Table 2, showing that the
addition of histological grade and lymphovascular invasion to
tumour size can improve further the accuracy with which these
parameters predict axillary lymph node status.
DISCUSSION
Over the last few years the surgical approach to breast cancer has
become less aggressive and the majority of patients have breast
conserving operations, with mastectomy being reserved for locally
advanced or multifocal tumours. However, in most specialist units
nearly all patients with invasive breast carcinoma undergo some
form of axillary dissection ranging from axillary sampling to a full
clearance. The importance of axillary lymph node status in deter-
mining prognosis in breast cancer and helping in the planning of
adjuvant therapy is widely accepted. Moreover, axillary clearance
contributes to the local control of the disease and reduces the
incidence of axillary recurrence (Kjaergaard et al, 1985; Benson
and Thorogood, 1986; Hayward and Caleffi, 1987). Harris and
Osteen (1985) have reported improved survival in patients
following axillary surgery, although most reports have shown that
survival remains unchanged (Fisher et al, 1985).
The potential benefits of axillary dissection must be balanced
against the well-known complications of this procedure (Benson
and Thorogood, 1986; Gutman et al, 1990; Hoe et al, 1992), such
as arm lymphoedema, sensory loss in the upper inner arm and
restriction of shoulder movements, which although rare and
usually short lived, can be very distressing to the patient.
Moreover, routine axillary dissection is associated with increased
hospital expense because of longer recovery time and stay in
hospital as well as longer operating time.
Early treatment failure, manifesting as local or distant tumour
recurrence, in node-negative patients has focused interest on some
other prognostic indicators. Tumour size has been related to prog-
nosis for many years (Fisher et al, 1969) and is an independent
predictor of disease-free and overall survival for both lymph node-
positive and negative patients (Crowe et al, 1992). Histological
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Figure 3 Axillary lymph node positivity (%) according to tumour size
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grade and lymphovascular invasion have also been shown to have
significant prognostic implications in patients with breast cancer,
more so in those with negative lymph nodes (Lauria et al, 1995;
Roberti, 1997).
With the introduction of breast screening, the presentation of
women with breast cancer has changed and early-stage tumours
are now diagnosed with ever-increasing frequency. Routine axil-
lary node clearance in all cases is, therefore, not justifiable and
for some early cancers not useful. In this series, nearly 25% of
patients had screen detected tumours, 55.4% had T1 tumours and
14.2% had tumours up to 1 cm in diameter. We feel that in the
absence of screening these figures would have been smaller.
Approximately, 45% of the patients in this study had axillary
lymph node metastases. Could the other 55% have been identified
preoperatively so that axillary dissection could have been
avoided? Our results confirm the direct relationship between
primary tumour histopathological characteristics such as size,
histological grade and lymphovascular invasion, and lymph node
status. None of the patients with DCIS and T1a tumours had axil-
lary metastases, but these were present in 16.3% and 35.7% of
cases with T1b and T1c tumours respectively. Lymphovascular
invasion was also a very important factor as 85% of tumours with
this feature were associated with nodal metastases, as compared to
only 15.4% of tumours without this feature. Similar figures have
been reported in a recent study in which axillary metastases were
present in 3% of patients with T1a tumours, however, the associa-
tion between lymphovascular invasion and axillary nodal posi-
tivity was not as strong as in our study (Silverstein et al, 1994).
The authors of this report suggested that axillary dissection is not
necessary for patients with T1a tumours as the yield of positive
lymph nodes is very small and only 1% of these patients will
benefit from any subsequent chemotherapy. Combinations of
various clinicopathological parameters can be more accurate
predictors of axillary nodal positivity and Barth showed that 49%
of patients with palpable, T1c, high nuclear grade tumours with
lymphovascular invasion had axillary lymph node metastases, as
compared to only 3% of those with T1a and T1b tumours and
without the other three risk factors (Barth et al, 1997). Similarly,
our study shows that the absence of lymphovascular invasion in
T1b, T1c and grade I T2 tumours is associated with a 9.9%, 25%
and 11.4% reduction in axillary node positivity respectively.
Based on the results presented and discussed here, we feel that
patients with operable breast cancer should be divided into three
categories: (a) those with DCIS and T1a tumours who do not
require routine axillary lymph node dissection; (b) those with T1b,
T1c and grade I T2 tumours in whom axillary dissection should be
carried out selectively depending on lymphovascular invasion and
other biological parameters including DNA ploidy, hormone
receptors, growth factors and their receptors, and oncogenes; and
(c) those with tumours greater than 2 cm in diameter or palpable
lymph nodes, in whom axillary dissection (usually clearance) is a
necessary intervention because of the high frequency of nodal
metastases. Although it has been argued that in the latter group
axillary dissection is not necessary because adjuvant treatment is
usually given (Cady, 1997), irrespective of nodal status, we feel
that axillary dissection improves local control of the disease and
by determining the extent of nodal involvement, it helps decide
which is the most appropriate chemotherapeutic regime.
The technique of sentinel lymph node biopsy first used in the
treatment of penile cancer (Cabanas, 1977) and malignant
melanoma (Morton et al, 1992), has recently been introduced in
the management of patients with breast cancer (Krag et al, 1993;
Giuliano et al 1994). Initial reports show high sensitivity and
specificity in predicting axillary lymph node status (Albertini et al,
1996), with few false-negative results, most of them in tumours
over 1.5 cm and those showing multifocality (Veronesi et al,
1997). We feel that this method could be very useful for all
patients with tumours in category b, i.e. T1b, T1c and grade I T2
tumours. It can be carried out, if appropriate, on a day-surgery
basis and depending on results, the patient will be selected for
further surgery if necessary. Another advantage of this method is
that it will permit a more detailed analysis of the one or two
sentinel lymph nodes removed, by examining multiple sections
and using immunohistochemistry. This intense histological exami-
nation will result in the detection of lymph node metastases, even
micrometastases, missed by current techniques (Giuliano et al,
1995). Evidence suggests that the detection of micrometastases
has prognostic significance and may help in the planning of adju-
vant therapy (McGuckin et al, 1996; Dowlatshahi et al, 1997).
We are entering a new era in the management of the axilla in
patients with breast cancer. Axillary dissection should be elimi-
nated for DCIS and T1a tumours and performed selectively for
patients with T1b, T1c and grade I T2 tumours. Primary tumour
characteristics such as size, histological type and grade, lympho-
vascular invasion, and expression of growth factors and oncogenes
will continue to provide valuable prognostic information and,
because of their correlation with axillary lymph node status,
should be used as criteria in selecting patients for axillary dissec-
tion. Moreover, sentinel lymph node biopsy will most probably
establish itself as an accurate axillary staging procedure for the
groups of patients discussed above.
Preoperative risk assessment is an important aspect of everyday
surgical practice. The management of breast cancer is no excep-
tion and patients should be given a clear account of the benefits
and risks of axillary dissection. We hope that the results presented
here can be useful in the preoperative counselling of patients with
breast cancer and contribute to the establishment of simple and
reliable criteria which will simplify the selection process for
axillary lymphadenectomy.
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